Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIIB
STRONG BUYBiogen Inc. · Healthcare · United States · $31.9B · Avg Vol: $238M/d
COMPANY DESCRIPTION
Biogen Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. The company holds a leading market position in multiple sclerosis treatments and is a pioneer in Alzheimer's disease research, backed by a robust R&D pipeline. Its specialized focus on neuroscience provides a distinct competitive advantage and addresses significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.2B | 9.8B | 9.7B | 9.9B | -0.9% | 9.9B | 10.0B | 10.3B | 2.3% |
| EPS | 20.96 | 8.02 | 11.21 | 8.83 | -25.0% | 9.30 | 7.63 | 9.60 | 4.3% |
| Shares | 144.0M | 144.9M | 145.7M | 146.8M | +1.9% | 147.6M | — | — | — |
| Debt | 6.6B | 7.3B | 6.6B | 6.6B | -0.2% | 6.6B | — | — | — |
| Equity | 13.4B | 14.8B | 16.7B | 18.3B | 10.9% | — | — | — | — |
| Op CF | 1.4B | 1.5B | 2.9B | 2.2B | 16.8% | 2.6B | — | — | — |
| Inv CF | 1.6B | -4.1B | -799.2M | -1.4B | — | — | — | — | — |
| Fin CF | -1.7B | 149.3M | -683.5M | -301.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIIB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIIB | Biogen Inc.(you) | $31.9B | 94 | STRONG BUY |
| PFE.DE | Pfizer Inc. | $138.0B | 94 | STRONG BUY |
| BMY | Bristol-Myers Squibb Company | $117.5B | 99 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $158.8B | 95 | STRONG BUY |
| AMGN.MX | Amgen Inc. | $192.8B | 96 | STRONG BUY |
| MRK | Merck & Co., Inc. | $317.8B | 93 | STRONG BUY |
| OGN | Organon & Co. | $3.5B | 98 | STRONG BUY |
| ABBV | AbbVie Inc. | $364.6B | 85 | STRONG BUY |
| JNJ.MX | Johnson & Johnson | $588.5B | 93 | STRONG BUY |
| LLY.MX | Eli Lilly and Company | $1.1T | 94 | STRONG BUY |
Peer medians: ROE -21.3% · P/E 27.3x · Gross margin 44.3%